| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Lei Ma, Ji Jia, Xiangyu Liu, Fuhai Bai, Qiang Wang, Lize Xion. Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. Biochemical and biophysical research communications. vol 458. issue 1. 2015-05-06. PMID:25637536. |
in this study, we used lipopolysaccharide (lps) plus interferon-γ (ifnγ) to activate n9 microglia and hypothesized the pretreatment with cannabinoid cb2 receptor agonist am1241 attenuates microglial activation by shifting microglial m1 to m2 state. |
2015-05-06 |
2023-08-13 |
Not clear |
| Lei Ma, Ji Jia, Xiangyu Liu, Fuhai Bai, Qiang Wang, Lize Xion. Activation of murine microglial N9 cells is attenuated through cannabinoid receptor CB2 signaling. Biochemical and biophysical research communications. vol 458. issue 1. 2015-05-06. PMID:25637536. |
however, these effects induced by am1241 pretreatment were significantly reversed in the presence of 10 μm cannabinoid cb2 receptor antagonist am630 or 10 μm protein kinase c (pkc) inhibitor chelerythrine. |
2015-05-06 |
2023-08-13 |
Not clear |
| Rosanna Chianese, Vincenza Ciaramella, Silvia Fasano, Riccardo Pierantoni, Rosaria Meccariell. Hypothalamus-pituitary axis: an obligatory target for endocannabinoids to inhibit steroidogenesis in frog testis. General and comparative endocrinology. vol 205. 2015-05-04. PMID:24566122. |
endocannabinoids - primarily anandamide (aea) and 2-arachidonoylglycerol (2-ag) - are lipophilic molecules that bind to cannabinoid receptors (cb1 and cb2). |
2015-05-04 |
2023-08-12 |
Not clear |
| Derek M Shore, Patricia H Reggi. The therapeutic potential of orphan GPCRs, GPR35 and GPR55. Frontiers in pharmacology. vol 6. 2015-04-30. PMID:25926795. |
however, the gpr55 endogenous ligand has been found to be a non-cannabinoid, lysophophatidylinositol (lpi) and subsequent high throughput assays have identified other gpr55 ligands that are not cannabinoids and do not bind to either the cannabinoid cb1 and cb2 receptors. |
2015-04-30 |
2023-08-13 |
Not clear |
| Megan J Dowie, Natasha L Grimsey, Therri Hoffman, Richard L M Faull, Michelle Glas. Cannabinoid receptor CB2 is expressed on vascular cells, but not astroglial cells in the post-mortem human Huntington's disease brain. Journal of chemical neuroanatomy. vol 59-60. 2015-04-23. PMID:24978314. |
cannabinoid cb2 receptors are localised and up-regulated on a number of peripheral immune cell types following inflammation and injury. |
2015-04-23 |
2023-08-13 |
human |
| Hai-Ying Zhang, Ming Gao, Qing-Rong Liu, Guo-Hua Bi, Xia Li, Hong-Ju Yang, Eliot L Gardner, Jie Wu, Zheng-Xiong X. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 46. 2015-04-23. PMID:25368177. |
cannabinoid cb2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. |
2015-04-23 |
2023-08-13 |
mouse |
| Hai-Ying Zhang, Ming Gao, Qing-Rong Liu, Guo-Hua Bi, Xia Li, Hong-Ju Yang, Eliot L Gardner, Jie Wu, Zheng-Xiong X. Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America. vol 111. issue 46. 2015-04-23. PMID:25368177. |
cannabinoid cb2 receptors (cb2rs) have been recently reported to modulate brain dopamine (da)-related behaviors; however, the cellular mechanisms underlying these actions are unclear. |
2015-04-23 |
2023-08-13 |
mouse |
| Timothy J England, William H Hind, Nadiah A Rasid, Saoirse E O'Sulliva. Cannabinoids in experimental stroke: a systematic review and meta-analysis. Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism. vol 35. issue 3. 2015-04-20. PMID:25492113. |
cannabinoids reduced infarct volume in transient (smd -1.41 (95% ci -1.71), -1.11) p<0.00001) and permanent (-1.67 (-2.08, -1.27), p<0.00001) ischemia and in all subclasses: endocannabinoids (-1.72 (-2.62, -0.82), p=0.0002), cb1/cb2 ligands (-1.75 (-2.19, -1.31), p<0.00001), cb2 ligands (-1.65 (-2.09, -1.22), p<0.00001), cannabidiol (-1.20 (-1.63, -0.77), p<0.00001), Δ(9)-tetrahydrocannabinol (-1.43 (-2.01, -0.86), p<0.00001), and hu-211 (-2.90 (-4.24, -1.56), p<0.0001). |
2015-04-20 |
2023-08-13 |
Not clear |
| Lih-Chu Chiou, Sherry Shu-Jung Hu, Yu-Cheng H. Targeting the cannabinoid system for pain relief? Acta anaesthesiologica Taiwanica : official journal of the Taiwan Society of Anesthesiologists. vol 51. issue 4. 2015-04-13. PMID:24529672. |
it is mainly mediated by its constituents, cannabinoids, through activating central cannabinoid 1 (cb1) receptors, as well as peripheral cb1 and cb2 receptors. |
2015-04-13 |
2023-08-12 |
Not clear |
| Esther Martínez-Martínez, Irene Gómez, Paloma Martín, Antonio Sánchez, Laura Román, Eva Tejerina, Félix Bonilla, Antonio García Merino, Antonio García de Herreros, Mariano Provencio, Jose M Garcí. Cannabinoids receptor type 2, CB2, expression correlates with human colon cancer progression and predicts patient survival. Oncoscience. vol 2. issue 2. 2015-04-10. PMID:25859556. |
cannabinoids receptor type 2, cb2, expression correlates with human colon cancer progression and predicts patient survival. |
2015-04-10 |
2023-08-13 |
human |
| Luara A Batista, Pedro H Gobira, Thercia G Viana, Daniele C Aguiar, Fabricio A Moreir. Inhibition of endocannabinoid neuronal uptake and hydrolysis as strategies for developing anxiolytic drugs. Behavioural pharmacology. vol 25. issue 5-6. 2015-03-31. PMID:25083569. |
the endocannabinoid system comprises the cb1 and cb2 receptors (the targets of the cannabis sativa compound delta-9-tetrahydrocannabinol), the endogenous ligands (endocannabinoids) arachidonoyl ethanolamide (anandamide) and 2-arachidonoyl glycerol, their synthesizing machinery and membrane transport system, and the hydrolyzing enzymes fatty acid amide hydrolase (faah) and monoacylglycerol lipase (magl), respectively. |
2015-03-31 |
2023-08-13 |
Not clear |
| Giovanni Pinna, Giovanni Loriga, Paolo Lazzari, Stefania Ruiu, Matteo Falzoi, Simona Frau, Amedeo Pau, Gabriele Murineddu, Battistina Asproni, Gerard A Pinn. Tricyclic pyrazoles. Part 6. Benzofuro[3,2-c]pyrazole: a versatile architecture for CB2 selective ligands. European journal of medicinal chemistry. vol 82. 2015-03-30. PMID:24922543. |
the novel compounds (15-24) were evaluated for their affinity to cb2 and cb1 cannabinoid receptors. |
2015-03-30 |
2023-08-13 |
Not clear |
| Longhe Yang, Yanting Li, Jie Ren, Chenggang Zhu, Jin Fu, Donghai Lin, Yan Qi. Celastrol attenuates inflammatory and neuropathic pain mediated by cannabinoid receptor type 2. International journal of molecular sciences. vol 15. issue 8. 2015-03-30. PMID:25101848. |
), a specific cannabinoid receptor-2 (cb2) receptor antagonist, but not by sr141716 (1 mg/kg, i.p. |
2015-03-30 |
2023-08-13 |
mouse |
| Maria Haustein, Robert Ramer, Michael Linnebacher, Katrin Manda, Burkhard Hin. Cannabinoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Biochemical pharmacology. vol 92. issue 2. 2015-03-20. PMID:25069049. |
increased cancer cell lysis by cbd was likewise abrogated when cbd-induced icam-1 expression was blocked by specific sirna or by antagonists to cannabinoid receptors (cb1, cb2) and to transient receptor potential vanilloid 1. |
2015-03-20 |
2023-08-13 |
Not clear |
| Elad Wasserman, Joseph Tam, Raphael Mechoulam, Andreas Zimmer, Gila Maor, Itai Ba. CB1 cannabinoid receptors mediate endochondral skeletal growth attenuation by Δ9-tetrahydrocannabinol. Annals of the New York Academy of Sciences. vol 1335. 2015-03-20. PMID:25573322. |
we show that cb1 and cb2 cannabinoid receptors are expressed specifically in hypertrophic chondrocytes of the epiphyseal growth cartilage (egc), which drives vertebrate growth. |
2015-03-20 |
2023-08-13 |
mouse |
| Mellar P Davi. Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands. Expert opinion on investigational drugs. vol 23. issue 8. 2015-03-10. PMID:24836296. |
cannabinoids in pain management: cb1, cb2 and non-classic receptor ligands. |
2015-03-10 |
2023-08-13 |
human |
| Obaid Afzal, Suresh Kumar, Rajiv Kumar, Ahmad Firoz, Manu Jaggi, Sandhya Baw. Docking based virtual screening and molecular dynamics study to identify potential monoacylglycerol lipase inhibitors. Bioorganic & medicinal chemistry letters. vol 24. issue 16. 2015-03-06. PMID:25011912. |
it hydrolyzes one of the major endocannabinoid, 2-arachidonoylglycerol (2-ag), an endogenous full agonist at g protein coupled cannabinoid receptors cb1 and cb2. |
2015-03-06 |
2023-08-13 |
human |
| Andrea Chicca, Diego Caprioglio, Alberto Minassi, Vanessa Petrucci, Giovanni Appendino, Orazio Taglialatela-Scafati, Jürg Gertsc. Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. ACS chemical biology. vol 9. issue 7. 2015-02-26. PMID:24831513. |
the widespread dietary plant sesquiterpene hydrocarbon β-caryophyllene (1) is a cb2 cannabinoid receptor-specific agonist showing anti-inflammatory and analgesic effects in vivo. |
2015-02-26 |
2023-08-13 |
Not clear |
| Andrea Chicca, Diego Caprioglio, Alberto Minassi, Vanessa Petrucci, Giovanni Appendino, Orazio Taglialatela-Scafati, Jürg Gertsc. Functionalization of β-caryophyllene generates novel polypharmacology in the endocannabinoid system. ACS chemical biology. vol 9. issue 7. 2015-02-26. PMID:24831513. |
while most changes on this element were detrimental for activity, ring-opening cross metathesis of 1 with ethyl acrylate followed by amide functionalization generated a series of new monocyclic amides (11a, 11b, 11c) that not only retained the cb2 receptor functional agonism of 1 but also reversibly inhibited fatty acid amide hydrolase (faah), the major endocannabinoid degrading enzyme, without affecting monoacylglycerol lipase (magl) and α,β hydrolases 6 and 12. |
2015-02-26 |
2023-08-13 |
Not clear |
| R Ribeiro, F Yu, J Wen, A Vana, Y Zhan. Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis. Neuroscience. vol 254. 2015-02-23. PMID:24036373. |
the protective mechanisms of cannabinoids are thought to be mediated by the activation of the cannabinoid type 1 (cb1) and type 2 (cb2) receptors expressed primarily in neurons and immune cells, respectively. |
2015-02-23 |
2023-08-12 |
mouse |